Aslam Ejaz MD, MPH is a surgical oncologist who specializes in the treatment of pancreatic cancer, liver cancer, bile duct cancer and other gastrointestinal cancers. In addition to his clinical work, he is dedicated to teaching the future generation of surgeons and other cancer care providers as an assistant professor in the Division of Surgical Oncology at The Ohio State University. As a member of the Translational Therapeutics Program at the OSUCCC – James, one of his research interests is in the development of clinical trials to help patients receive new therapies that may not be available at other treatment centers. He is also interested in researching how patients do after surgery as well as addressing variations in perioperative surgical care and quality improvement. Dr. Ejaz’s research is dedicated to improving cancer care, and he has published over 100 peer-reviewed papers in high-impact cancer and surgical journals. Dr. Timothy M. Pawlik, MD, PhD, MPH, MTS, MBA, FACS, FSSO is the Chair of Surgery at The Ohio State University Wexner Medical Center where he holds The Urban Meyer III and Shelley Meyer Chair for Cancer Research. His research focuses on determinations of factors associated with prognosis and staging of gastrointestinal cancers with a particular focus on cholangiocarcinoma. He also studies patient/physician communication and patient engagement, as well as patient perception of cancer-care goals and the impact of social determinants of health. Dr. Pawlik is an active participant in multiple national and international surgical societies and has delivered talks on cholangiocarcinoma around the world.

• 1.Epidemiology and Risk Factors for Metastatic Colorectal Disease 2.Molecular Pathogenesis, Tumor Microenvironment and Future Therapeutic Targets: Colorectal Liver Metastasis 3.Pre-operative Imaging, Response Evaluation, and Surgical Planning – CT, PET, Radiomics, FLR Measurement 4.Use of Molecular Markers and Other Personalized factors in Treatment Decisions (KRAS, sidedness etc.) 5.Role of Neoadjuvant Therapy in Treatment of Patients with Colorectal Liver Metastasis 6.Management of the Disappeared Colorectal Liver Metastasis 7.Approach to Small Liver Remnant – Strategies to Increase Resectability 8.Two-Stage versus ALPPS for Large Intrahepatic Burden of Colorectal Liver Metastasis 9.Synchronous Colorectal Liver Metastasis – Simultaneous vs. Staged Approach 10.Minimally Invasive Approaches to Metastatic Colorectal Cancer 11.Hepatic Resection of Colorectal Liver Metastasis in the Presence of Extrahepatic Disease 12.Locoregional Approaches to Colorectal Liver Metastasis – Ablation 13.Locoregional Approaches to Colorectal Liver Metastasis - Intra-arterial 14.Locoregional Approaches to Colorectal Liver Metastasis - Radiation Options 15.Adjuvant Therapy following Resection of Colorectal Liver Metastasis 16.Long-term Prognosis and Surveillance of Patients with Resected Colorectal Liver Metastasis17.Management of Secondary Recurrence of Intra-hepatic Colorectal Liver Metastasis following Initial Hepatic Resection 18.Immunotherapy and Targeted Therapies for Colorectal Liver Metastasis 19.Colorectal Liver Metastasis: Survivorship

Aslam Ejaz MD, MPH is a surgical oncologist who specializes in the treatment of pancreatic cancer, liver cancer, bile duct cancer and other gastrointestinal cancers. In addition to his clinical work, he is dedicated to teaching the future generation of surgeons and other cancer care providers as an assistant professor in the Division of Surgical Oncology at The Ohio State University. As a member of the Translational Therapeutics Program at the OSUCCC – James, one of his research interests is in the development of clinical trials to help patients receive new therapies that may not be available at other treatment centers. He is also interested in researching how patients do after surgery as well as addressing variations in perioperative surgical care and quality improvement. Dr. Ejaz’s research is dedicated to improving cancer care, and he has published over 100 peer-reviewed papers in high-impact cancer and surgical journals. Dr. Timothy M. Pawlik, MD, PhD, MPH, MTS, MBA, FACS, FSSO is the Chair of Surgery at The Ohio State University Wexner Medical Center where he holds The Urban Meyer III and Shelley Meyer Chair for Cancer Research. His research focuses on determinations of factors associated with prognosis and staging of gastrointestinal cancers with a particular focus on cholangiocarcinoma. He also studies patient/physician communication and patient engagement, as well as patient perception of cancer-care goals and the impact of social determinants of health. Dr. Pawlik is an active participant in multiple national and international surgical societies and has delivered talks on cholangiocarcinoma around the world.

• 1.Epidemiology and Risk Factors for Metastatic Colorectal Disease 2.Molecular Pathogenesis, Tumor Microenvironment and Future Therapeutic Targets: Colorectal Liver Metastasis 3.Pre-operative Imaging, Response Evaluation, and Surgical Planning – CT, PET, Radiomics, FLR Measurement 4.Use of Molecular Markers and Other Personalized factors in Treatment Decisions (KRAS, sidedness etc.) 5.Role of Neoadjuvant Therapy in Treatment of Patients with Colorectal Liver Metastasis 6.Management of the Disappeared Colorectal Liver Metastasis 7.Approach to Small Liver Remnant – Strategies to Increase Resectability 8.Two-Stage versus ALPPS for Large Intrahepatic Burden of Colorectal Liver Metastasis 9.Synchronous Colorectal Liver Metastasis – Simultaneous vs. Staged Approach 10.Minimally Invasive Approaches to Metastatic Colorectal Cancer 11.Hepatic Resection of Colorectal Liver Metastasis in the Presence of Extrahepatic Disease 12.Locoregional Approaches to Colorectal Liver Metastasis – Ablation 13.Locoregional Approaches to Colorectal Liver Metastasis - Intra-arterial 14.Locoregional Approaches to Colorectal Liver Metastasis - Radiation Options 15.Adjuvant Therapy following Resection of Colorectal Liver Metastasis 16.Long-term Prognosis and Surveillance of Patients with Resected Colorectal Liver Metastasis17.Management of Secondary Recurrence of Intra-hepatic Colorectal Liver Metastasis following Initial Hepatic Resection 18.Immunotherapy and Targeted Therapies for Colorectal Liver Metastasis 19.Colorectal Liver Metastasis: Survivorship

Aslam Ejaz MD, MPH is a surgical oncologist who specializes in the treatment of pancreatic cancer, liver cancer, bile duct cancer and other gastrointestinal cancers. In addition to his clinical work, he is dedicated to teaching the future generation of surgeons and other cancer care providers as an assistant professor in the Division of Surgical Oncology at The Ohio State University. As a member of the Translational Therapeutics Program at the OSUCCC – James, one of his research interests is in the development of clinical trials to help patients receive new therapies that may not be available at other treatment centers. He is also interested in researching how patients do after surgery as well as addressing variations in perioperative surgical care and quality improvement. Dr. Ejaz’s research is dedicated to improving cancer care, and he has published over 100 peer-reviewed papers in high-impact cancer and surgical journals. Dr. Timothy M. Pawlik, MD, PhD, MPH, MTS, MBA, FACS, FSSO is the Chair of Surgery at The Ohio State University Wexner Medical Center where he holds The Urban Meyer III and Shelley Meyer Chair for Cancer Research. His research focuses on determinations of factors associated with prognosis and staging of gastrointestinal cancers with a particular focus on cholangiocarcinoma. He also studies patient/physician communication and patient engagement, as well as patient perception of cancer-care goals and the impact of social determinants of health. Dr. Pawlik is an active participant in multiple national and international surgical societies and has delivered talks on cholangiocarcinoma around the world.

• 1.Epidemiology and Risk Factors for Metastatic Colorectal Disease 2.Molecular Pathogenesis, Tumor Microenvironment and Future Therapeutic Targets: Colorectal Liver Metastasis 3.Pre-operative Imaging, Response Evaluation, and Surgical Planning – CT, PET, Radiomics, FLR Measurement 4.Use of Molecular Markers and Other Personalized factors in Treatment Decisions (KRAS, sidedness etc.) 5.Role of Neoadjuvant Therapy in Treatment of Patients with Colorectal Liver Metastasis 6.Management of the Disappeared Colorectal Liver Metastasis 7.Approach to Small Liver Remnant – Strategies to Increase Resectability 8.Two-Stage versus ALPPS for Large Intrahepatic Burden of Colorectal Liver Metastasis 9.Synchronous Colorectal Liver Metastasis – Simultaneous vs. Staged Approach 10.Minimally Invasive Approaches to Metastatic Colorectal Cancer 11.Hepatic Resection of Colorectal Liver Metastasis in the Presence of Extrahepatic Disease 12.Locoregional Approaches to Colorectal Liver Metastasis – Ablation 13.Locoregional Approaches to Colorectal Liver Metastasis - Intra-arterial 14.Locoregional Approaches to Colorectal Liver Metastasis - Radiation Options 15.Adjuvant Therapy following Resection of Colorectal Liver Metastasis 16.Long-term Prognosis and Surveillance of Patients with Resected Colorectal Liver Metastasis17.Management of Secondary Recurrence of Intra-hepatic Colorectal Liver Metastasis following Initial Hepatic Resection 18.Immunotherapy and Targeted Therapies for Colorectal Liver Metastasis 19.Colorectal Liver Metastasis: Survivorship